Financhill
Sell
48

MDGL Quote, Financials, Valuation and Earnings

Last price:
$299.54
Seasonality move :
-0.06%
Day range:
$287.46 - $299.58
52-week range:
$200.08 - $377.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.52x
P/B ratio:
9.34x
Volume:
359.8K
Avg. volume:
363.7K
1-year change:
37.1%
Market cap:
$6.6B
Revenue:
$180.1M
EPS (TTM):
-$18.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MDGL
Madrigal Pharmaceuticals
$114.2M -$3.79 985.75% -48.55% $421.93
ALNY
Alnylam Pharmaceuticals
$581.2M -$0.37 -5.56% -8.95% $320.56
BBIO
BridgeBio Pharma
$57.7M -$1.00 4530.37% -18.53% $58.17
CYTK
Cytokinetics
$2.6M -$1.36 527.09% -8.55% $74.76
GERN
Geron
$48.5M -$0.04 16309.12% -60.37% $4.13
UTHR
United Therapeutics
$729.3M $6.54 12.23% 25.78% $388.18
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MDGL
Madrigal Pharmaceuticals
$298.83 $421.93 $6.6B -- $0.00 0% 20.52x
ALNY
Alnylam Pharmaceuticals
$276.55 $320.56 $36.1B -- $0.00 0% 15.14x
BBIO
BridgeBio Pharma
$35.82 $58.17 $6.8B -- $0.00 0% 53.11x
CYTK
Cytokinetics
$33.04 $74.76 $3.9B -- $0.00 0% 199.23x
GERN
Geron
$1.31 $4.13 $834.3M -- $0.00 0% 10.99x
UTHR
United Therapeutics
$306.92 $388.18 $13.8B 12.25x $0.00 0% 4.95x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MDGL
Madrigal Pharmaceuticals
14.24% 1.767 1.61% 5.41x
ALNY
Alnylam Pharmaceuticals
89.88% 1.597 2.91% 2.84x
BBIO
BridgeBio Pharma
925.32% 1.067 28.12% 4.31x
CYTK
Cytokinetics
168.01% 0.673 13.74% 5.89x
GERN
Geron
29.71% 1.799 5.52% 5.04x
UTHR
United Therapeutics
2.85% 1.506 1.44% 5.05x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MDGL
Madrigal Pharmaceuticals
$132.7M -$79.3M -43.17% -49.57% -50.96% -$88.9M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
BBIO
BridgeBio Pharma
$114M -$103.8M -145.93% -- -109.29% -$200.8M
CYTK
Cytokinetics
-$98.3M -$155.6M -121.06% -- -8766.94% -$137.3M
GERN
Geron
$46.8M -$20.1M -45.4% -59.29% -35.02% -$43.8M
UTHR
United Therapeutics
$701.9M $382.8M 18.69% 19.92% 54.08% $386.3M

Madrigal Pharmaceuticals vs. Competitors

  • Which has Higher Returns MDGL or ALNY?

    Alnylam Pharmaceuticals has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -9.67%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About MDGL or ALNY?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 41.2%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.56 which suggests that it could grow by 15.91%. Given that Madrigal Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Madrigal Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    ALNY
    Alnylam Pharmaceuticals
    12 8 1
  • Is MDGL or ALNY More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

  • Which is a Better Dividend Stock MDGL or ALNY?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or ALNY?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.52x versus 15.14x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.52x -- $137.3M -$73.2M
    ALNY
    Alnylam Pharmaceuticals
    15.14x -- $594.2M -$57.5M
  • Which has Higher Returns MDGL or BBIO?

    BridgeBio Pharma has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -143.55%. Madrigal Pharmaceuticals's return on equity of -49.57% beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    BBIO
    BridgeBio Pharma
    97.74% -$0.88 $209.5M
  • What do Analysts Say About MDGL or BBIO?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 41.2%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.17 which suggests that it could grow by 62.39%. Given that BridgeBio Pharma has higher upside potential than Madrigal Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    BBIO
    BridgeBio Pharma
    10 3 0
  • Is MDGL or BBIO More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

  • Which is a Better Dividend Stock MDGL or BBIO?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or BBIO?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.52x versus 53.11x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.52x -- $137.3M -$73.2M
    BBIO
    BridgeBio Pharma
    53.11x -- $116.6M -$167.4M
  • Which has Higher Returns MDGL or CYTK?

    Cytokinetics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -10220.14%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Cytokinetics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    CYTK
    Cytokinetics
    -6223.05% -$1.36 $391.7M
  • What do Analysts Say About MDGL or CYTK?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 41.2%. On the other hand Cytokinetics has an analysts' consensus of $74.76 which suggests that it could grow by 126.28%. Given that Cytokinetics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Cytokinetics is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    CYTK
    Cytokinetics
    10 3 0
  • Is MDGL or CYTK More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

  • Which is a Better Dividend Stock MDGL or CYTK?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or CYTK?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Cytokinetics quarterly revenues of $1.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than Cytokinetics's net income of -$161.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.52x versus 199.23x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.52x -- $137.3M -$73.2M
    CYTK
    Cytokinetics
    199.23x -- $1.6M -$161.4M
  • Which has Higher Returns MDGL or GERN?

    Geron has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -53.33%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Geron's return on equity of -59.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    GERN
    Geron
    98.35% -$0.04 $398.8M
  • What do Analysts Say About MDGL or GERN?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 41.2%. On the other hand Geron has an analysts' consensus of $4.13 which suggests that it could grow by 214.89%. Given that Geron has higher upside potential than Madrigal Pharmaceuticals, analysts believe Geron is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    GERN
    Geron
    4 2 0
  • Is MDGL or GERN More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

  • Which is a Better Dividend Stock MDGL or GERN?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or GERN?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Geron quarterly revenues of $47.5M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Geron's net income of -$25.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.52x versus 10.99x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.52x -- $137.3M -$73.2M
    GERN
    Geron
    10.99x -- $47.5M -$25.4M
  • Which has Higher Returns MDGL or UTHR?

    United Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of 40.56%. Madrigal Pharmaceuticals's return on equity of -49.57% beat United Therapeutics's return on equity of 19.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    UTHR
    United Therapeutics
    88.36% $6.63 $7B
  • What do Analysts Say About MDGL or UTHR?

    Madrigal Pharmaceuticals has a consensus price target of $421.93, signalling upside risk potential of 41.2%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 26.48%. Given that Madrigal Pharmaceuticals has higher upside potential than United Therapeutics, analysts believe Madrigal Pharmaceuticals is more attractive than United Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    UTHR
    United Therapeutics
    6 6 0
  • Is MDGL or UTHR More Risky?

    Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

  • Which is a Better Dividend Stock MDGL or UTHR?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or UTHR?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than United Therapeutics's net income of $322.2M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.52x versus 4.95x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.52x -- $137.3M -$73.2M
    UTHR
    United Therapeutics
    4.95x 12.25x $794.4M $322.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 6.67% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 1.33% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock